Contact Support: 512-708-4678

Newsletter

GET THE BUZZ ON CONTINUING MEDICAL EDUCATION COURSES
New Course Alerts and CME News

HCV VOICE II: Optimizing Virological Outcomes With Integrated HCV Education
Vindico

Memphis, TN
Apr 01, 2015

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death from liver disease in the United States. The discovery, development, and availability of direct-acting antiviral agents (DAAs) offers new treatment options and the possibility of improved outcomes for newly diagnosed patients, as well as those who have experienced a relapse or failed to respond to previous treatment. However, their use introduces new challenges and adds to the complexity of HCV treatment and care. HCV-TARGET is an international consortium of academic and community investigators prospectively enrolling patients treated with HCV regimens that include a DAA to assess the effects of HCV therapy in the broader population. The HCV-TARGET initiative aims to continue to evaluate the safety and efficacy of HCV regimens, including a robust data set of traditionally underrepresented patient populations, such as those with cirrhosis, null responders, older adults, African Americans, Hispanics, and patients infected with mutated strains of HCV. Effective management of HCV continues to pose a challenge for health care practitioners. The purpose of this unique HCV VOICE II initiative is to provide specific, targeted educational opportunities for clinicians who are involved in the management of patients with HCV. This CME activity will consider real-world data of patients treated with new regimens to provide an understanding of how and when specific regimens are most beneficial, particularly in challenging patients with HCV genotype 1, and will review the current HCV practice guidelines and how and when to use the new treatment regimens.


Upon successful completion of this activity, participants will be able to:

  • Apply the 2014 AASLD practice guidelines to real-world case scenarios representative of difficult to treat patient populations with hepatitis C.
  • Examine real-world data, in addition to clinical trial data, when determining the most appropriate treatment course for challenging patients with genotype 1 HCV.
  • Assess the safety and efficacy of newly approved second generation DAA regimens in challenging patients with genotype 1 HCV.



The intended audience for this activity is gastroenterologists, hepatologists, nurse practitioners, physician assistants, and other health care professionals involved in the treatment of patients with hepatitis C virus (HCV).


5 minutes: Introduction & PreTest

65 minutes: Interactive Case Evaluation and Expert Faculty Analysis: Real-World Management of HCV Genotype 1 in 2014

5 minutes: PostTest

15 minutes: Faculty/Audience Discussion, Question & Answer, Closing Remarks

There is no fee for this activity.

Click here to register.

Purdue University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Purdue University designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



For full CME information, faculty bios, presentation schedule, and program details, please visit HCVVOICE.com.